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Abstract
Toll-like receptors play an essential role in our innate immune system and are a focus of interest in contemporary cancer
research. Thus far, Toll-like receptors have shown promising prognostic value in carcinomas of the oral cavity, colon, and
ovaries, but the prognostic role of Toll-like receptors in pancreatic ductal adenocarcinoma has not been established. We
set out to investigate whether Toll-like receptor expression could serve in prognostic evaluation in pancreatic ductal
adenocarcinoma, as well. Our study comprised 154 consecutive stage I–III pancreatic ductal adenocarcinoma patients
surgically treated at Helsinki University Hospital between 2002 and 2011. Patients who received neoadjuvant therapy
were excluded. Tissue microarrays and immunohistochemistry allowed assessment of the expression of Toll-like recep-
tor 2 and Toll-like receptor 4 in pancreatic ductal adenocarcinoma tissue, and we matched staining results against clinico-
pathological parameters using Fisher’s test. For survival analysis, we used the Kaplan–Meier method and the log-rank
test, and the Cox regression proportional hazard model for univariate and multivariate analyses. The hazard ratios were
calculated for disease-specific overall survival. Strong Toll-like receptor 2 expression was observable in 51 (34%) patients
and strong Toll-like receptor 4 in 50 (33%) patients. Overall, neither marker showed any direct coeffect on survival.
However, strong Toll-like receptor 2 expression predicted better survival when tumor size was less than 30 mm (hazard
ratio = 0.30; 95% confidence interval = 0.13–0.69; p = 0.005), and strong Toll-like receptor 4 expression predicted better
survival in patients with lymph-node-negative disease (hazard ratio = 0.21; 95% confidence interval = 0.07–0.65;
p = 0.006). In conclusion, we found strong Toll-like receptor 2 and Toll-like receptor 4 expressions to be independent
factors of better prognosis in pancreatic ductal adenocarcinoma patients with stage I–II disease.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a notably
aggressive disease and a common cause of cancer
death.1 The only curative treatment is radical surgery
combined with oncological treatment. Yet PDAC is
notorious in its tendency to metastasize early on, and
only approximately 15%–20% of patients have resect-
able disease.2,3 The 5-year survival rate is less than
4%,4 and even those who undergo radical intent sur-
gery have a 5-year survival of only approximately
20%.5
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A well-known risk factor for cancer development is
chronic local inflammation, presumably due to local
release of anti-apoptotic, angiogenic, and growth-
stimulating factors.6 However, the role of inflammation
is complex, as it exhibits also antitumor properties.7
Toll-like receptors (TLRs) take part in first-line
immune defense: they occur in sentinel immune cells
and epithelia. Their main purpose is to activate local
inflammation response and to enhance adaptive immu-
nity and cell proliferation. They work through MyD88
proteins, which induce NF-kB activation and ultimately
cell proliferation.8 They are activated by unfamiliar
molecules, either particles of microbial origin or endo-
genic components released in tissue damage.
TLRs are also overexpressed in some carcinomas,
which have led to their exploration as prognostic mar-
kers and targets for oncological treatment. TLRs have
been studied in numerous carcinomas, with strong
expression usually being associated with worse prog-
nosis.9–12 TLRs 2 and 4 have also been studied in
PDAC, but no prognostic value has been noted thus
far.13,14
Our aim was to explore the prognostic roles of
TLR2 and TLR4 in PDAC. These receptors are among
those linked to bacterial infections and are two of the
most studied TLRs in relation to cancer.15 Our hypoth-
esis was that TLR2 and TLR4 expressions show prog-
nostic value in PDAC patients.
Materials and methods
The data came from consecutive surgically treated
PDAC patients who underwent surgery in 2002–2011
at the Department of Surgery, Helsinki University
Hospital, with 21 receiving neoadjuvant therapy
excluded. Those seven rediagnosed with stage-IV meta-
static disease were likewise excluded. Four patients
were excluded on the grounds of insufficient data. This
left us with 154 PDAC patient samples to analyze.
Survival data and cause of death came from the
Finnish Population Registry, from Statistics Finland,
and from hospital records.
Surgical tissue samples were stored fixed in formalin
and were embedded in paraffin at the Department of
Pathology, Helsinki University Hospital. These
archived samples were deparaffinized in xylene and
rehydrated with a decreasing concentration of ethanol.
Subsequently, they were stained with hematoxylin and
eosin. All tumor samples were re-evaluated by experi-
enced pathologists to ensure correct PDAC diagnosis.
Multipunch tissue microarray blocks (TMAs) were
prepared from the tissue samples. First, representative
regions were chosen and marked on the hematoxylin–
eosin stained slides, and with their guidance, 1.0mm
cores were cut from the paraffin blocks with a semiau-
tomatic tissue microarrayer (Tissue Arrayer 1, Beecher
Instruments Inc., Silver Spring, MD, USA). Six cores
were taken from each patient to optimize TMA
representativeness.
The TMA blocks were cut into 4mm sections and
then deparaffinized and rehydrated. The slides were
then treated in Tris-HCL (pH 8.5) buffer for 20min at
98C and incubated at room temperature for 18 h in
the appropriate antibody solution. For TLR2, rabbit
polyclonal antibody TLR2 (H-175): sc-10739 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA; 1:50) and
for TLR4, rabbit polyclonal antibody TLR4 (H-80):
sc-10741 (Santa Cruz Biotechnology; 1:50) were used.
Expression of TLR2 and TLR4 in PDAC tissue was
assessed by the intensity of the staining and scored on a
scale from 0 to 3, where 0 indicated negative staining,
and 1, 2, and 3 indicated mild, moderate, and strong
staining, respectively. Staining intensity was evaluated
by two independent observers (M.A.L. and J.K.H.) and
in cases with different scores, discussion led to consen-
sus. The initial interobserver agreement was evaluated
using Cohen’s kappa coefficient.
Staining results were matched against clinicopatho-
logical parameters with Fisher’s test. We applied the
Kaplan–Meier method and log-rank test for survival
analysis. The Cox regression proportional hazard
model served for univariate and multivariate analyses,
and the hazard ratios (HRs) were calculated for
disease-specific overall survival. The Cox model
assumption of constant HR over time was tested by
including time-dependent covariates separately for each
variable. The inclusion of covariates was based on clini-
cal relevance. The HRs for TLR4 were analyzed during
two time periods from 0 to 3.75 years and later on, by
dividing the time axis to meet the Cox model assump-
tion. Exact 95% confidence intervals (CIs) were calcu-
lated for survival rates. Spearman’s rho correlation
coefficient served to assess the correlation between
TLR scores and clinical parameters. Due to the low
number of TLR-negative patients, TLR scores 0 and 1
were combined for statistical purposes for both TLR2
and TLR4. If a patient had different scores for different
samples, the highest was the choice for that patient.
Statistical analyses were performed with SPSS version
24.0 (IBM SPSS Statistics, version 24.0; SPSS, Inc.,
Chicago, IL, USA, an IBM Company), and with SAS
version 9.4 (SAS Institute Inc., Cary, NC, USA).
This study was approved by the Helsinki University
Hospital Surgical Ethics Committee (document number
HUS 226/E6/06, additional petition TMK02 § 66/2013)
and the Finnish National Supervisory Authority for




We obtained successful TLR2 scores from 153 patients
and TLR4 scores from 152 patients. Both TLR2 and
TLR4 were stained evenly in the cytoplasm with no dis-
tinctive membranous staining. In most samples, healthy
pancreatic epithelium remained negative, although in
some samples even normal pancreatic ductal epithelium
showed positivity. In two TLR4 samples, healthy epithe-
lium was positive, whereas cancerous tissue was not, but
with no distinctive nuclear staining (Figure 1). Before
reaching unanimity, the initial interobserver agreement
was k=0.48 for TLR2 and k=0.52 for TLR4.
Strong TLR2 expression was observable in 51 (34%)
patients and strong TLR4 expression in 50 (33%)
patients. Expression of neither marker associated directly
with patient survival when all data were analyzed.
However, survival advantage of strong TLR2 and
TLR4 expressions was clearly noticeable during the
first few years after surgery, in different subpopula-
tions. Among patients with small (ł 30mm) tumors,
the cumulative survival of those with negative or mild
TLR2 expression at 1 year after surgery was 42% (95%
CI=15%–67%), whereas among those with moderate
TLR2 expression, it was 81% (95% CI=64%–90%),
and with strong TLR2 expression, 82% (95%
CI=59%–93%); Sidak-corrected log rank for strong
versus negative or mild TLR2 expression p=0.032.
Likewise, among patients with lymph-node-negative
disease, survival at 1 year after surgery with negative or
mild TLR4 expression was 50% (95% CI=15%–
78%), with moderate TLR4 expression 84% (95%
CI=63%–94%), and with strong TLR4 expression
93% (95% CI=61%–99%); Sidak-corrected log-rank
for strong versus negative or mild TLR4 expression
p=0.11 (Figure 2).
No significant survival differences between different
TLR2 groups emerged when patients with tumor size
.30mm were added to the analysis, as neither with
TLR4 groups when patients with lymph-node-positive
disease were included. A statistically significant weak
correlation appeared between TLR2 and TLR4 expres-
sions, r=0.28, p=0.001, but no correlation between
TLR expression and age, gender (Tables 1 and 2), or
C-reactive protein (CRP) level emerged (for TLR2 and
CRP r=0.071, p=0.424; for TLR4 and CRP
r=0.111, p=0.213).
Multivariate analysis showed that strong
(HR=0.30; 95% CI=0.13–0.69; p=0.005) or mod-
erate (HR=0.42; 95% CI=0.20–0.88; p=0.021)
TLR2 expression in patients with tumor size 30mm or
less showed an overall survival benefit over patients
with low or negative TLR2 expression. In patients with
lymph-node-negative disease, strong (HR=0.21; 95%
CI=0.07–0.65; p=0.006) and moderate (HR=0.37;
95% CI=0.15–0.91; p=0.030) TLR4 expression pro-
vided more survival benefit than low or negative TLR4
expression during the first 3.75 years (Tables 3 and 4).
This same survival benefit was also noticeable in
Figure 1. Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4) staining. Immunopositivity scoring: For TLR2, (a–d) show
negative, mild, moderate, and strong staining. For TLR4, (e–h) show negative, mild, moderate, and strong staining.
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multivariate 5-year survival analysis for both TLR2
and TLR4 (see supplementary tables 5–7). All the HRs
were calculated for disease-specific overall survival
unless otherwise specified.
Discussion
We found strong TLR2 and TLR4 expressions indepen-
dently to indicate better prognosis in PDAC patients
with stage I–II disease. To our knowledge, we report
for the first time the expression of TLR2 in PDAC. The
expression of TLR4 and its association with prognosis
in PDAC has been reported earlier in two studies.14,15
In PDAC, TLR4 expression has been associated
with more advanced disease and poor patient outcome,
and pancreatic TLR4 expression has been higher in
cancerous cells than in normal epithelial cells. A posi-
tive association between TLR4 expression and tumor
size, lymph-node involvement, venous invasion, and
pathological stage has also appeared.14 According to
that 2010 report, TLR4 was not identifiable as an
independent prognostic factor—its associated features
such as tumor size, disease stage, and venous invasion
carry a heavy prognostic load themselves, and stage I–
II patients were not a focus of that study. The study
consisted only of 65 PDAC patients. Our relatively
large series of 154 patients allowed us to focus more on
stage I–II patients. Our study also differed from that
2010 report in the methods: we used TMA and immu-
nohistochemistry (IHC), whereas they measured TLR4
mRNA by real-time PCR and TLR4 protein immu-
noexpression. We used the same antibody. In our sam-
ples, immunopositivity was primarily cytoplasmic,
while in their work, the cell membranes also high-
lighted. The reason for this difference in staining pat-
tern is unclear.
A recent study did not find any prognostic value for
TLR2 and TLR4 in PDAC in 65 resected PDAC
patients.15 They evaluated TLR2 and TLR4 expres-
sions in PDAC by IHC as did we, but their approach
was different. They evaluated separately membranous,
nuclear, and cytoplasmic staining and the proportion
of affected epithelial cancer cells. They used these data
Figure 2. Survival in all patients, grouped by (a) Toll-like receptor 2 (TLR2) expression and (b) Toll-like receptor 4 (TLR4)
expression. (c) Survival in patients with small tumor size (<30 mm), grouped by TLR2 expression. (d) Survival with lymph-node-
negative disease, grouped by TLR4 expression.
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Table 1. Associations between Toll-like receptor 2 (TLR2) immunoexpression and clinicopathological parameters, n = 153.
TLR2 expression Negative Low Moderate Strong p value
N (%) 2 (1.3) 17 (11) 82 (54) 52 (34)
Age, years
\65 0 (0) 4 (23.5) 25 (30.5) 14 (26.9) 0.793
ø65 2 (100) 13 (76.5) 57 (69.5) 38 (73.1)
Gender
Male 0 (0) 8 (47.1) 42 (51.2) 35 (67.3) 0.023
Female 2 (100) 9 (52.9) 40 (48.8) 17 (32.7)
Stagea
I 1 (50) 2 (11.8) 16 (19.5) 8 (15.4) 0.886
II 1 (50) 15 (88.2) 63 (76.8) 44 (84.6)
III 0 (0) 0 (0) 3 (3.7) 0 (0)
Lymph-node ratio
\20% 2 (100) 15 (88.2) 59 (72.0) 42 (80.8) 1.000
ø20% 0 (0) 2 (11.8) 23 (28.0) 9 (17.3)
Missing data 0 (0) 0 (0) 0 (0) 1 (1.9)
Tumor size
<30 mm 1 (50) 11 (64.7) 37 (45.1) 22 (42.3) 0.104
.30 mm 0 (0) 5 (29.4) 43 (52.4) 29 (55.8)
Missing data 1 (50) 1 (5.9) 2 (2.4) 1 (1.9)
Perineural invasion
Yes 2 (100) 13 (76.5) 53 (64.6) 32 (61.5) 0.367
No 0 (0) 2 (11.8) 17 (20.7) 11 (21.2)
Missing data 0 (0) 2 (11.8) 12 (14.6) 9 (17.3)
Perivascular invasion
Yes 0 (0) 3 (17.6) 23 (28.0) 16 (30.8) 0.130
No 2 (100) 11 (64.7) 46 (56.1) 24 (46.2)
Missing data 0 (0) 3 (17.6) 13 (15.9) 12 (23.1)
AJCC: American Joint Committee on Cancer.
p values \0.05 in bold. Correlation evaluated by linear-by-linear association test.
aStaging according to AJCC 7th edition.
Table 2. Associations between Toll-like receptor 4 (TLR4) immunoexpression and clinicopathological parameters, n = 152.
TLR4 expression Negative Low Moderate Strong p value
N (%) 3 (2.0) 32 (21) 67 (44) 50 (33)
Age, years
\65 0 (0) 9 (28.1) 21 (31.3) 12 (24.0) 1.000
ø65 3 (100) 23 (71.9) 46 (68.7) 38 (76.0)
Gender
Male 1 (33.3) 17 (53.1) 35 (52.2) 30 (60.0) 0.407
Female 2 (66.7) 15 (46.9) 32 (47.8) 20 (40.0)
Stagea
I 0 (0) 5 (15.6) 12 (17.9) 10 (20.0) 0.459
II 3 (100) 26 (81.3) 54 (80.6) 39 (78.0)
III 0 (0) 1 (3.1) 1 (1.5) 1 (2.0)
Lymph-node ratio
\20% 3 (100) 23 (71.9) 50 (74.6) 41 (82.0) 0.457
ø20% 0 (0) 9 (28.1) 17 (25.4) 8 (16.0)
Missing data 0 (0) 0 (0) 0 (0) 1 (2.0)
Tumor size
<30 mm 0 (0) 18 (56.2) 27 (40.3) 23 (46.0) 0.466
.30 mm 1 (33) 14 (43.8) 37 (55.2) 25 (50.0)
Missing data 2 (66.7) 0 (0) 3 (4.5) 2 (4.0)
Perineural invasion
Yes 3 (100) 22 (68.8) 45 (67.2) 30 (60.0) 0.432
No 0 (0) 7 (21.9) 10 (14.9) 12 (24.0)
Missing data 0 (0) 3 (9.4) 12 (17.9) 8 (16.0)
Perivascular invasion
Yes 0 (0) 10 (31.2) 19 (28.4) 14 (28.0) 0.813
No 2 (66.7) 19 (59.4) 33 (49.3) 27 (54.0)
Missing data 1 (33.3) 3 (9.4) 15 (22.4) 9 (18.0)
AJCC: American Joint Committee on Cancer.
Correlation evaluated by linear-by-linear association test.
aStaging according to AJCC 7th edition.
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to calculate a histoscore for each type of staining. They
found no survival benefit for membranous, nuclear, or
cytoplasmic staining. The staining patterns in their
results were different from ours: they noted cytoplasmic
staining in all PDAC cells for both TLR2 and TLR4,
and membranous staining for some of the cells (24/65
for TLR2; 25/65 for TLR4). They also noted nuclear
staining in their samples (42/65 for TLR2, 5/65 for
TLR4). In our results, staining was cytoplasmic with
no distinctive membranous or nuclear staining, and we
also found PDAC cells unstained in the cytoplasm for
TLR2 and TLR4. The difference in staining pattern
may result from different antibodies used: theirs were
from Abnova, whereas ours were from Santa Cruz. As
the patient number in their study was markedly lower
than in ours, sub-group analysis was not possible to the
same extent as in our work.
Given the setting, it was intriguing to find an associ-
ation between expression of TLR2 and TLR4 and
better prognosis in stage I–II PDAC patients. Most
earlier studies have demonstrated a TLR association
with poor prognosis in various cancers. In hepatocellu-
lar carcinoma, TLR4 expression has not only been
linked to metastatic disease,16,17 and in colorectal can-
cer to poorer prognosis,11 but interestingly also to non-
metastatic disease.18 In esophageal cancer, the associa-
tion between TLR4 and prognosis was negative.19
TLR2 and TLR4 have also been studied in squamous
cell carcinoma of the tongue, where both have been
linked to invasion.12 In Merkel cell carcinoma, cyto-
plasmic TLR2 has been linked to small tumor size, but
nuclear TLR2 expression to larger tumors, and nuclear
TLR4 expression to older age. However, no prognostic
value of TLRs emerged in Merkel cell carcinomas.20
TLR2 has been studied less widely than TLR4, and
apart from its association with small tumor size in
Merkel cell carcinoma, to our knowledge, no results
similar to ours have appeared. We wish to see further
Table 3. Univariate and multivariate survival analyses of patients with pancreatic ductal adenocarcinoma according to
clinicopathological parameters and TLR2 and TLR4 immunoexpression.
Survival analyses
Univariate (n = 154) Multivariate (n = 153)
HR 95% CI p value HR 95% CI p value
Age, years
\65 1.00 1.00
ø65 1.21 0.81–1.79 0.346 1.26 0.84–1.89 0.271
Gender
Male 1.00 1.00
Female 0.90 0.65–1.31 0.650 0.90 0.62–1.32 0.592
Stagea LNR
IA–IIA 1.00 0.000 1.00 0.000
IIB, III \20% 1.40 0.92–2.14 0.116 1.62 1.02–2.58 0.042
IIB, III ø20% 2.91 1.79–4.74 0.000 3.33 1.99–5.58 0.000
Tumor size, mm
<30 1.00
.30 1.38 0.97–1.96 0.073
Perineural invasion
No 1.00
Yes 1.30 0.83–2.03 0.249
Perivascular invasion
No 1.00
Yes 1.81 1.21–2.70 0.004
TLR2
Negative or mild 1.00 0.722 1.00 0.709
Moderate 0.98 0.57–1.70 0.957 0.93 0.53–1.63 0.805
Strong 0.85 0.48–1.51 0.576 0.81 0.44–1.49 0.490
TLR4
Negative or mild 1.00 0.388 1.00 0.444
Moderate 0.88 0.56–1.39 0.587 1.02 0.63–1.63 0.948
Strong 0.73 0.45–1.16 0.184 0.77 0.45–1.31 0.328
TLR: Toll-like receptor; LNR: lymph-node ratio; CI: confidence interval; HR: hazard ratio; AJCC: American Joint Committee on Cancer.
Univariate and multivariate Cox analyses. The hazard ratios are calculated for disease-specific overall survival. Multivariate analysis is adjusted for age,
gender, stage, LNR, and post-adjuvant treatment. Two multivariate analyses were performed separately to TLR2 and TLR4. Multivariate
clinicopathological parameters data shown are from TLR2 model (TLR4 data not shown). Multivariate TLR4 hazard ratios valid for the first
3.75 years. p values \0.05 in bold.
aStaging according to AJCC 7th edition.
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investigations elucidating whether increased TLR2
expression shows any positive prognostic value in
patients with diverse cancers of small tumor size.
Similarly, to our knowledge, no reports of divergent
significance have involved TLR4 expression in patients
with lymph-node-negative disease compared to expres-
sion in patients who are lymph-node-positive. What
would be worthwhile would be to investigate whether
similar phenomena occur in other cancers, as well.
At diagnosis, only 15%–20% of diagnosed PDACs
are operable,2,3 which skews our patient pool. From
most patients, no histological specimen or biopsy is
available for screening of tissue biomarkers. In addi-
tion, our positive findings concerned only those fortu-
nate patients with local disease and are not necessarily
applicable to those with more advanced, non-operable
disease. Nevertheless, we hope that these results may be
of help in developing specific, post-operative treatment
options for patients with various cancer-related
immunological profiles, small tumors, and those with
lymph-node-negative disease.
TLRs initiate and strengthen the local inflammation
response, which may help create a tumor-promoting
microenvironment through anti-apoptotic, angiogenic,
and growth-stimulating factors.6 Cell debris from
tumor-induced necrosis can activate TLRs, leading to a
self-perpetuating cycle resulting in increased necrosis
and inflammation, thus encouraging tumor progression
and metastasis. This process could help explain the neg-
ative association between strong TLR expression and
cancer survival in general, but our findings in PDAC
are contradictory.
One reason for our findings may be the exceptional
aggressiveness of PDAC—we only had a negligible
number of truly TLR-negative PDAC patients, which
we combined with score-1 patients for statistical pur-
poses. If negative TLR2 or TLR4 expression has a pos-
itive association with PDAC prognosis, it may not
Table 4. Multivariate sub-group analysis of pancreatic ductal adenocarcinoma patients with tumor size <30 mm and lymph-node-
negativity, according to TLR2 and TLR4 immunoexpression.
Hazard ratio 95% CI p value
Multivariate analysis, primary tumor size <30 mm (n = 71)
Age, years
\65 1.00
ø65 1.44 0.77–2.66 0.252
Gender
Male 1.00
Female 0.77 0.43–1.39 0.389
Stagea LNR
IA–IIA 1.00 0.247
IIB, III \20% 1.22 0.64–2.32 0.549
IIB, III ø20% 2.07 0.88–4.84 0.094
Post-adjuvant treatment
No 1.00
Yes 0.79 0.45–1.40 0.418
TLR2
Negative or mild 1.00 0.016
Moderate 0.42 0.20–0.88 0.021
Strong 0.30 0.13–0.69 0.005
Multivariate analysis in lymph-node-negative patients (n = 48)
Age, years
\65 1.00
ø65 1.44 0.60–3.47 0.414
Gender
Male 1.00
Female 0.72 0.35–1.50 0.385
Post-adjuvant treatment
No 1.00
Yes 0.90 0.39–2.11 0.816
TLR4
Negative or mild 1.00 0.020
Moderate 0.37 0.15–0.91 0.030
Strong 0.21 0.07–0.65 0.006
TLR: Toll-like receptor; LNR: lymph-node ratio; CI: confidence interval; AJCC: American Joint Committee on Cancer.
Multivariate Cox analysis. Multivariate analysis adjusted for age, gender, stage, LNR, and post-adjuvant treatment. Multivariate TLR4 hazard ratios
valid for the first 3.75 years. The hazard ratios are calculated for disease-specific overall survival. p values \0.05 in bold.
aStaging according to AJCC 7th edition.
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have come to light in our material. Another possible
explanation is that the circumstances of stage I–II
PDAC simply favor more the antitumor effects of
TLRs.7 A notable clinical illustration of the antitumor
effects of TLR2 and TLR4 is Mycobacterium bovis
Bacillus Calmette-Guérin (BCG), a TLR2 and TLR4
agonist, which is widely used in the treatment of local
bladder carcinoma.21 The strong desmoplastic reaction
seen in PDAC22 may affect the tumor microenviron-
ment balance in such a way that lack of TLR2- and
TLR4-induced cytokines actually promotes tumor pro-
gression and metastasis. This could explain why our
results only apply to patients with early, localized
PDAC, as the specific tissue microenvironment interac-
tion may be highly dependent on tumor stage.22
The TMA technique permits the use of a larger num-
ber of patients. Its most notable downside is that only
certain areas of the tumor can be evaluated, allowing
sampling error. To counter this effect, we took six cores
from various parts of the tumor, both from its invasive
front and its center, thus minimizing potential error.
IHC evaluation is subjective by nature. Our interobser-
ver agreement was not ideal, and this may influence our
results. To minimize this, we re-evaluated and discussed
all differing scores after independent evaluation.
Considering the low incidence of operable PDAC, our
patient number is quite large. We excluded patients receiv-
ing neoadjuvant therapy on the premise that it may alter
the tumor microenvironment and skew results. Many of
our patients were treated earlier in the 2000s, when neoad-
juvant therapy was less common, which left us with a
unique opportunity to include inflammation markers in
tumor tissue unaffected by chemo- or radiotherapy.
In conclusion, here we show that in PDAC, TLR2
and TLR4 expressions correlate with better prognosis
in patients with small tumor size and lymph-node-
negative disease. Further investigation needs to validate
these results.
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